Skip to main content
Top
Published in: Rheumatology International 8/2017

01-08-2017 | Cases with a Message

Etanercept-induced leukemia: could increased mean corpuscular volume be a predictor of hematologic malignancy?

Authors: Döndü Üsküdar Cansu, Hava Üsküdar Teke, Cengiz Korkmaz

Published in: Rheumatology International | Issue 8/2017

Login to get access

Abstract

In rheumatology practice, anti-tumor necrosis factor (TNF) alpha agents are frequently used medications, more so in ankylosing spondylitis (AS). There are case reports, besides their adverse effects, such as infection and injection site reaction, suggesting these agents may cause solid or hematologic malignancies. Acute leukemia secondary to anti-TNF alpha agents has been rarely reported in patients with AS. In this case report, based on a patient who developed acute leukemia while on the treatment with etanercept, we will discuss whether it is possible to predict acute leukemia by monitoring the mean corpuscular volume in light of the literature.
Literature
1.
go back to reference Nanau RM, Neuman MG (2014) Safety of anti-tumor necrosis factor therapies in arthritis patients. J Pharm Pharm Sci 17:324–361CrossRefPubMed Nanau RM, Neuman MG (2014) Safety of anti-tumor necrosis factor therapies in arthritis patients. J Pharm Pharm Sci 17:324–361CrossRefPubMed
2.
go back to reference Bakland G, Nossent H (2003) Acute myelogenous leukaemia following etanercept therapy. Rheumatology (Oxford) 42:900–901CrossRef Bakland G, Nossent H (2003) Acute myelogenous leukaemia following etanercept therapy. Rheumatology (Oxford) 42:900–901CrossRef
3.
go back to reference Bachmeyer C, Thiolière B, Khosrotehrani K, Cattan E (2007) Acute myelogenous leukemia in a patient receiving etanercept for psoriasis. J Am Acad Dermatol 56:169–170CrossRefPubMed Bachmeyer C, Thiolière B, Khosrotehrani K, Cattan E (2007) Acute myelogenous leukemia in a patient receiving etanercept for psoriasis. J Am Acad Dermatol 56:169–170CrossRefPubMed
4.
go back to reference Nair B, Raval G, Mehta P (2007) TNF-alpha inhibitor etanercept and hematologic malignancies: report of a case and review of the literature. Am J Hematol 82:1022–1024CrossRefPubMed Nair B, Raval G, Mehta P (2007) TNF-alpha inhibitor etanercept and hematologic malignancies: report of a case and review of the literature. Am J Hematol 82:1022–1024CrossRefPubMed
5.
go back to reference Knudson RM, Tefferi A, Pittelkow MR, Davis MD (2011) Development of myelodysplastic syndrome evolving to acute myeloid leukemia in a patient receiving etanercept for psoriasis. J Am Acad Dermatol 65:673–674CrossRefPubMed Knudson RM, Tefferi A, Pittelkow MR, Davis MD (2011) Development of myelodysplastic syndrome evolving to acute myeloid leukemia in a patient receiving etanercept for psoriasis. J Am Acad Dermatol 65:673–674CrossRefPubMed
6.
go back to reference Sadlier M, Connaghan G, Kirby B (2012) Acute myeloid leukemia presenting with cutaneous infiltrates in a patient receiving etanercept for chronic lymphocytic vasculitis. J Am Acad Dermatol 67:e264–e265CrossRefPubMed Sadlier M, Connaghan G, Kirby B (2012) Acute myeloid leukemia presenting with cutaneous infiltrates in a patient receiving etanercept for chronic lymphocytic vasculitis. J Am Acad Dermatol 67:e264–e265CrossRefPubMed
7.
go back to reference Ferrer-Marín F, Amigo ML, Vicente V (2012) Leukaemic transformation in patients with haematological disease receiving tumour necrosis factor inhibitors. Clin Drug Investig 32:423–426CrossRefPubMed Ferrer-Marín F, Amigo ML, Vicente V (2012) Leukaemic transformation in patients with haematological disease receiving tumour necrosis factor inhibitors. Clin Drug Investig 32:423–426CrossRefPubMed
8.
go back to reference Cesarini M, Vernia P, Angelucci E (2010) Acute lymphoid leukemia in a Crohn’s disease patient during treatment with adalimumab after a prolonged treatment with azathioprine and steroids. Inflamm Bowel Dis 16:371–372CrossRefPubMed Cesarini M, Vernia P, Angelucci E (2010) Acute lymphoid leukemia in a Crohn’s disease patient during treatment with adalimumab after a prolonged treatment with azathioprine and steroids. Inflamm Bowel Dis 16:371–372CrossRefPubMed
9.
go back to reference Kemta Lekpa F, Zahra K, Pautas C, Maury S, Chevalier X, Claudepierre P (2009) Acute myeloid leukemia after infliximab: a case report. Clin Exp Rheumatol 27:999–1000PubMed Kemta Lekpa F, Zahra K, Pautas C, Maury S, Chevalier X, Claudepierre P (2009) Acute myeloid leukemia after infliximab: a case report. Clin Exp Rheumatol 27:999–1000PubMed
10.
go back to reference Takahashi N, Kameoka J, Takahashi N, Tamai Y, Murai K, Honma R et al (2016) Causes of macrocytic anemia among 628 patients: mean corpuscular volumes of 114 and 130 fL as critical markers for categorization. Int J Hematol 104:344–357CrossRefPubMed Takahashi N, Kameoka J, Takahashi N, Tamai Y, Murai K, Honma R et al (2016) Causes of macrocytic anemia among 628 patients: mean corpuscular volumes of 114 and 130 fL as critical markers for categorization. Int J Hematol 104:344–357CrossRefPubMed
11.
go back to reference Tennant GB, Al-Sabah AI, Burnett AK (2002) Prognosis of myelodysplasic patients: non-parametric multiple regression analysis of populations stratified by mean corpuscular volume and marrow myeloblast number. Br J Haematol 119:87–96CrossRefPubMed Tennant GB, Al-Sabah AI, Burnett AK (2002) Prognosis of myelodysplasic patients: non-parametric multiple regression analysis of populations stratified by mean corpuscular volume and marrow myeloblast number. Br J Haematol 119:87–96CrossRefPubMed
12.
go back to reference Mercer LK, Galloway JB, Lunt M, Davies R, Low AL, Dixon W et al (2017) Risk of lymphoma in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis 76:497–503 Mercer LK, Galloway JB, Lunt M, Davies R, Low AL, Dixon W et al (2017) Risk of lymphoma in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis 76:497–503
13.
go back to reference Harigai M, Nanki T, Koike R, Tanaka M, Watanabe-Imai K, Komano Y et al (2016) Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan. Mod Rheumatol 26:642–650CrossRefPubMed Harigai M, Nanki T, Koike R, Tanaka M, Watanabe-Imai K, Komano Y et al (2016) Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan. Mod Rheumatol 26:642–650CrossRefPubMed
14.
15.
go back to reference Hellgren K, Dreyer L, Arkema EV, Glintborg B, Jacobsson LT, Kristensen L et al (2017) Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers. Ann Rheum Dis 76:105–111 Hellgren K, Dreyer L, Arkema EV, Glintborg B, Jacobsson LT, Kristensen L et al (2017) Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers. Ann Rheum Dis 76:105–111
16.
go back to reference Tsimberidou AM, Giles FJ (2002) TNF-alpha targeted therapeutic approaches in patients with hematologic malignancies. Expert Rev Anticancer Ther 2:277–286CrossRefPubMed Tsimberidou AM, Giles FJ (2002) TNF-alpha targeted therapeutic approaches in patients with hematologic malignancies. Expert Rev Anticancer Ther 2:277–286CrossRefPubMed
Metadata
Title
Etanercept-induced leukemia: could increased mean corpuscular volume be a predictor of hematologic malignancy?
Authors
Döndü Üsküdar Cansu
Hava Üsküdar Teke
Cengiz Korkmaz
Publication date
01-08-2017
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 8/2017
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-017-3687-4

Other articles of this Issue 8/2017

Rheumatology International 8/2017 Go to the issue